T
Tünde Csépány
Researcher at University of Debrecen
Publications - 72
Citations - 1643
Tünde Csépány is an academic researcher from University of Debrecen. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 16, co-authored 60 publications receiving 1361 citations. Previous affiliations of Tünde Csépány include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
Howard Amital,Zoltán Szekanecz,Gabriella Szücs,Katalin Dankó,Endre Nagy,Tünde Csépány,E. Kiss,Jozef Rovensky,A. Tuchynova,Darina Kozakova,Andrea Doria,N. Corocher,Nancy Agmon-Levin,Vivian Barak,Hedi Orbach,Gisele Zandman-Goddard,Yehuda Shoenfeld +16 more
TL;DR: In a cohort of patients with SLE originating from Israel and Europe vitamin D serum concentrations were found to be inversely related to disease activity.
Journal ArticleDOI
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.
Hedi Orbach,Gisele Zandman-Goddard,Gisele Zandman-Goddard,Howard Amital,Howard Amital,Vivian Barak,Zoltán Szekanecz,Gabriella Szücs,Katalin Dankó,Endre Nagy,Tünde Csépány,Jozélio Freire de Carvalho,Andrea Doria,Yehuda Shoenfeld,Yehuda Shoenfeld +14 more
TL;DR: HPRL, hyperferritinemia, hypovitaminosis D, and TPA levels did not correlate with SLE activity elevated levels of rheumatoid factor or anti‐CCP antibodies in RA, and have different immunological implications in the pathogenesis of the autoimmune diseases.
Journal ArticleDOI
Sequence specificity of mRNA N6-adenosine methyltransferase
TL;DR: Localization of six new N6-methyladenosine sites on Rous sarcoma virus (RSV) virion RNA has confirmed the extended consensus sequence for methylation: RGACU, where R is usually a G (7/12).
Journal ArticleDOI
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
Tomas Kalincik,Tomas Kalincik,Dana Horakova,Tim Spelman,Vilija Jokubaitis,Maria Trojano,Alessandra Lugaresi,Guillermo Izquierdo,Csilla Rozsa,Pierre Grammond,Raed Alroughani,Pierre Duquette,Marc Girard,Eugenio Pucci,Jeannette Lechner-Scott,Mark Slee,Ricardo Fernandez-Bolanos,Francios Grand'Maison,Raymond Hupperts,Freek Verheul,Suzanne Hodgkinson,Celia Oreja-Guevara,Daniele Spitaleri,Michael Barnett,Murat Terzi,Roberto Bergamaschi,Pamela A. McCombe,Jose Luis Sanchez-Menoyo,Magdolna Simó,Tünde Csépány,Garbor Rum,Cavit Boz,Eva Havrdova,Helmut Butzkueven,Helmut Butzkueven,Helmut Butzkueven +35 more
TL;DR: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod, but no studies have directly compared the outcomes of switching to either of these agents.
Journal ArticleDOI
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Tomas Kalincik,Tomas Kalincik,J William L Brown,J William L Brown,Neil Robertson,Mark Willis,Neil J Scolding,Neil J Scolding,Claire M Rice,Claire M Rice,Alastair Wilkins,Alastair Wilkins,Owen R Pearson,Tjalf Ziemssen,Michael Hutchinson,Christopher McGuigan,Vilija Jokubaitis,Vilija Jokubaitis,Tim Spelman,Tim Spelman,Dana Horakova,Eva Havrdova,Maria Trojano,Guillermo Izquierdo,Alessandra Lugaresi,Alexandre Prat,Marc Girard,Pierre Duquette,Pierre Grammond,Raed Alroughani,Eugenio Pucci,Patrizia Sola,Raymond Hupperts,Jeannette Lechner-Scott,Murat Terzi,Vincent Van Pesch,Csilla Rozsa,Francois Grand'Maison,Cavit Boz,Franco Granella,Mark Slee,Daniele Spitaleri,Javier Olascoaga,Roberto Bergamaschi,Freek Verheul,Steve Vucic,Pamela A. McCombe,Suzanne Hodgkinson,Jose Luis Sanchez-Menoyo,Radek Ampapa,Magdolna Simó,Tünde Csépány,Cristina Ramo,Edgardo Cristiano,Michael Barnett,Helmut Butzkueven,Helmut Butzkueven,Helmut Butzkueven,Alasdair Coles +58 more
TL;DR: Both natalizumab and alemtuzumab seem highly effective and viable immunotherapies for multiple sclerosis and seem to have similar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.